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Purpose: To evaluate the cost of antibacterial usage to patients in a tertiary health facility in Nigeria. 
Methods:  Drug utilization evaluation was carried out retrospectively among patients with sexually 
transmitted infections (STIs) over a one-year period between 2005 and 2006 in Lagos University 
Teaching Hospital (LUTH), Nigeria. Case notes numbering 230 and containing 317 prescriptions were 
sampled consecutively with the aid of diagnostic coding cards. Relevant data including case 
demographics, diagnosis, prescribed drugs, and dosages were extracted and the associated costs 
analysed.   
Results: A majority of the patients (82.3 %) were youths aged 21 - 40 years. Higher prevalence was 
observed among male patients (70.2 %). The proportion of drugs prescribed in generic and branded 
names were 82.1 and 17.9 %, respectively. Total number of antibacterial doses was 7284 at a total cost 
of NGN239,420.00 (US$1,841.69). Average antibacterial cost per patient was NGN1,040.96 (US$8.00).  
Quinolones were the most widely prescribed class of antibacterial agents (31.1 % of cases) at a cost of 
NGN81,646.00 (US$628.05) representing 34.1% of  the total antibacterial cost to patients.      
Conclusion: This study indicates that antibacterial cost was high, relative to the purchasing power of 
the local populace, a large proportion of whom live below the poverty line (US$1.00 per day). 
Furthermore, a greater proportion of the antibacterial cost was due to a few agents, the use of which 
should be evidence-based and closely monitored. 
 















*Corresponding author:  E-mail: suleimanismail@yahoo.com; Tel: +234-8023433337
Suleiman & Tayo  
Trop J Pharm Res, December 2010; 9(6): 550 
INTRODUCTION 
 
Sexually transmitted infections (STIs) such as 
syphilis, gonorrhoea, chancroid, chlamydia 
and non gonococcal urethritis are very 
common worldwide and a total prevalence of 
21.5% has been reported in Nigeria [1]. STIs 
have considerable impact on the health of 
adolescents and young adults. Most of them 
are usually students, unemployed and stand 
the risk of poor management if contracted. In 
the year 2000, an estimated nine million 
cases of STIs occurred among persons aged 
15 - 24 years in the United States [2]. Bowei, 
in 2006, estimated 332 million cases of STIs 
worldwide among adults aged 15 - 49 years 
[3]. A total prevalence of about 3.7 million 
cases was reported in Nigeria in 2001 [4]. It 
probably has not changed much since then. 
Therefore, STIs are of immense public health 
importance and is an area where more 
information is needed.  STIs are also closely 
associated with HIV infection [5]. Relevant 
educational interventions in STIs 
management should enhance the capacity to 
reduce HIV transmission. 
      
Expenditures on health are increasing 
worldwide and often health care systems 
have difficulties in meeting their obligations. 
Increasing longevity, higher prevalent rates of  
diseases, increasing antimicrobial resistance, 
more expensive diagnostic and therapeutic 
options, amongst others, often necessitate 
general increment in healthcare 
expenditures.   
 
Allocated budget to health has been low in 
Nigeria (< 5 %), which is considerably less 
than the 15 % recommended by World Health 
Organisation (WHO) [6,7]. Consequently, 
healthcare managers in low-income 
countries, such as Nigeria, are indirectly 
being asked to do more with less and are, 
therefore, faced with challenge of rational 
decision-making [8]. Out of pocket expense, 
a major funding option of healthcare services 
in Nigeria is very limited, as many live below 
the poverty line, earning less than US$ 1.00 
per day [9].    
Meanwhile, cost-related studies are very rare 
in many developing countries. In 1997, Taylor 
et al reported high cost of parenteral 
antibacterial therapy and long duration of 
hospitalization in Lagos, Nigeria [10].  In the 
report, a cost ranging from NGN600.00 
(US$4.62) to NGN32,987.00 (US$253.75) 
was incurred by patients who were admitted 
for a period ranging from of 1 to 67 days. A 
gross irrational use of antibacterial agents 
was also documented with the use of 26 
different antibacterial agents in the treatment 
of six major infections with a combination of 
two to five drugs per treatment regimen [9]. 
The cost implication of STIs treatment is 
compounded because of externality, 
resistance to antibacterial agents, 
complications such as infertility from pelvic 
inflammatory disease and non-adherence to 
treatment regimen.  
 
This paper seeks to evaluate the cost to 
patients of antibacterial usage in a tertiary 
health facility in Lagos, Nigeria, as the 
findings could form the basis for decision-






The study was carried out in the 764-bed 
Lagos University Teaching Hospital (LUTH), 
Lagos, Nigeria which is a tertiary health care 
centre. The hospital comprises Accident and 
Emergency Unit as well as various in-patient 
and general out-patient units, among others. 
Total patient turnover in the hospital is 
approx. 10,000 monthly. Various specialties 
and wards as well as diagnostic facilities are 
in place in the hospital. Antibacterial agents, 
if indicated, are prescribed in all the 
departments for surgical and medical cases. 
Each of the major hospital units has a 
pharmacy unit attached.  
 
Study design    
 
It was a retrospective drug utilization 
evaluation involving the use of consecutively 
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sampled case notes over a one-year period 
between 2005 and 2006.  
 
Data collection  
 
Two hundred and thirty case notes containing 
317 prescriptions pertaining to STIs were 
used. Relevant data such as date of visit, 
demographics, diagnosis, type of diagnostic 
test, prescribed drugs, dosages, frequency of 
dosing, and duration of therapy, were 
extracted. Follow-up visit, if any, and test of 
cure (a repeat diagnostic test within a month 
of therapy to ascertain complete eradication 
of infection or otherwise) were also collected 
using an appropriately designed and 




Clinical and economic outcome variables 
were used. The clinical outcome measure 
used was assumed bacterial eradication. 
Economic outcome used was the 
antibacterial cost as a component of direct 
medical cost. There was no adjustment for 
discounting and inflation as all the costs 
occurred within one year of analysis. 
However, the exchange rate (between the 
Nigerian naira or NGN and United States 
dollar or US$) at the time of analysis was 




The collected data were analysed using Epi 
Info 2002 (CDC, USA).  Mean cost per 
defined daily dose (C/DDD) [11] and the total 
cost of antibacterial agents per visit for each 
patient were computed for each drug. Also 
determined were the proportions of 
prescriptions in generic and branded names, 
the cost of each class of antibacterial agents, 
and number of visits. The volume of usage in 
doses for each drug and class of antibacterial 
agents were also computed. Data were 
analysed using Chi square test and Fisher’s 
exact test (for small numbers) while mean 
costs were compared using Student’s t-test. 
Descriptive statistics (mean and %) were 
used in the presentation of results. At 95 % 
confidence interval, a 2-tailed p-value less 




Demographic data and hospital visits 
 
A majority of the patients (82.3 %) were 
youths aged 21 - 40 years. First-time visit to 
the hospital by patients was 72.6 % while 
follow-up visit to the hospital was very low 




Non-specific urethritis was the most prevalent 
STI and occurred among 43.2 % of the 
patients, followed by vaginitis and 
syphilis/genital ulcer at the rate of 13.2 and 
11.0 %, respectively. Others were genital 
warts (3.8 %), gonorrhoea (2.7 %), chlamydia  
(1.6 %), chancroid (3.5 %), pelvic inflamma-
tory disease (2.7 %), cervicitis (2.2 %) and 
prostatitis (2.2 %).  
 
Treatments were, in several cases, largely 
empirical as diagnostic tests were carried out 
in 53.6 % of the patients, out of which 46.0 % 
was microscopy culture and sensitivity (mcs). 
The test of cure rate for mcs test was very 
low (11.9 %), as Table 2 indicates. The most 
commonly isolated organism (n = 59) was 
Staphylococcus aureus, 20 (33.8 %). Others 
include Escherichia coli, 10 (16.9 %); 
Klebsiella spp, 8 (13.5%); and other 




The proportion of drugs prescribed in their 
generic names was 82.1 % which is 
significantly higher than those prescribed in 
their brand names (χ
2
; p < 0.05). Mean 
number of drugs per prescription was 1.8 and 
the volume of antibacterial agents prescribed 
in doses was 7284. Quinolones constituted 
31.1 % of the total prescriptions with 
ciprofloxacin being the most frequent (19.9 
%) and 11.2 % for other quinolones.  
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              Table 1: Demographic data and hospital visit among STIs patients  
 











11-20 11(3.5) 16 (5.1) 21(6.6) 6 (1.9) 27 (8.5) 
21-30 86 (27.1) 56 (17.7) 97 (30.6) 45 (14.2) 142 (44.8) 
31-40       103 (32.5)      16 (5.1)           89 (28.1)     30 (9.5)             119 (37.5)                         
41-50       17 (5.4)          4 (1.3)              17 (5.4)      4 (1.3)                21 (6.6) 
51-60       4 (1.3)           0 (0.0)               3 (0.9)        1 (0.3)                4 (1.3) 
> 60          3 (0.9)            1 (0.3)              3 (0.9)         1 (0.3)                4 (1.3) 
Total 224 (70.7)      93 (29.3)          230 (72.6)   87 (27.4)             317 (100.0) 
      STIs = sexually transmitted Infections                  
 
                Table 2: Documented cases of diagnostic test among STI patients   
 








Microscopy/Culture/Sensitivity 112 (35.3) 59 (46.0) 7 (11.9) 
 (VDT) 54 (17.0) 6 (11.1) 0 (0.0) 
Chlamydial Test 2 (0.6) 1 (50.0) 0(0.0) 
TPHA 2 (0.6) 0 (0.0) - 
Total 170 (53.6) 66 (20.8) 7(11.9) 
             STIs = Sexually transmitted infections; VDT = venereal disease test; TPHA = Treponema pallidum  
         haemagglutination assay 
 
 
Cost variables  
 
The total antibacterial cost to all the patients 
over one year period was NGN239,420.00 
(US$1841.69). Of this, the quinolones formed 
the largest proportion - NGN81,646.00 
(US$628.95) or 34.1%. Ciprofloxacin, which 
was the most prescribed quinolone (19.9 %), 
constituted 8.5 % of the total antibacterial 
cost and 25.2 % of the total quinolone cost 
while other quinolones with a prescription 
frequency of 11.2 % constituted a statistically 
significant higher cost proportion of 74.8 % of 
all the quinolones. A tenth (11.1 %) of the 
total antibacterial cost was accounted for by 
the cephalosporins but was prescribed at a 
rate of only 1.4 %. Azithromycin (a macrlide) 
also constituted 3.6 % of total antibacterial 
cost despite being prescribed at a rate of 0.5 
%. The mean cost per single dose was 
NGN32.86 (US$0.25) while the mean 
antibacterial cost per patient was 





The antibacterial drug cost (to the patients 
and health care systems) of treating the 
various infections was enormous. One 
thousand cases of urethritis, the most 
prevalent, and chlamydial infections required 
NGN664,000 (US$5107.69) and  NGN3.4 
million (US$26153.85), respectively. A 
median STIs treatment cost of US$17.80 
(NGN2314.00) has been reported in a 
systematic review for low-and middle-income 
countries [12]. These costs are huge and 
were borne mostly by youths who are 
economically disadvantaged being predomi-
nantly students or unemployed. This 
excludes other costs such as diagnostic test, 
transportation, consultation and loss of 
productivity.  
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      Table 3: Antibacterial cost for the treatment of sexually transmitted infections  
 




Total drug cost 
 NGN (US$) 
 
Drug cost (%) 
Quinolones Ciprofloxacin 113(19.9) 20,556.00(158.12) 8.5 
 Others 64 (11.2) 61,090.00(469.92) 25.6 
 Subtotal 177(31.1) 81,646.00(628.95) 34.1 
Tetracycline Doxycycline 163(28.6) 33,018.00(253.98) 13.8 
 Tetracycline 3 (0.5) 640.00(4.92) 0.3 
 Subtotal 166(29.2) 33, 658.00 (258.90) 14.0 
Cephalosporins Ceftriaxone 3(0.5) 14,218.00(109.37) 6.0 
 Cefuroxime 5(0.9) 12,300.00 (94.62) 5.1 
 Subtotal 8(1.4) 26,518.00(203.98 ) 11.1 
Macrolides Erythromycin 65(11.4) 33,616.00(258.58 ) 14.0 
 Azithromycin 3(0.5) 8606.00(66.2) 3.6 
 Subtotal 68(11.9) 42,222.00(324.78) 17.5 
Others Subtotal 150(26.3) 55,376.00(425.97) 23.3 
 Grand total 569(100.0) 239,420.00(1841.69) 100.0 
 
      Note: Exchange rate at the time of the study was US$1 = NGN130; no adjustment for inflation or discounting was     
      made 
                
 
Accurate diagnosis is important to ensure 
optimal use of limited resources but this is not 
affordable to most of the affected patients 
and the health care system, hence syndromic 
management of STIs has been 
recommended [4]. Antibacterial therapy 
needs to be specific while empiric 
prescription should be minimized by 
strengthening necessary capacity building 
such as improving diagnostic facilities. This, 
in turn, will reduce cost and improve the 
quality of management. In this study, generic 
prescribing was more prevalent than brand 
name prescription; this should be sustained 
as it also reduces costs significantly [13].   
 
The documented cases of diagnostic tests 
was found in about half of the patients, which 
implies that treatments were, in a large 
number of cases, empirical, and this could be 
a major factor in the development of bacterial 
resistance [14,15].  Non-affordability of these 
tests could, however, be another problem 
encountered by the patients.  
 
The much lower cost of ciprofloxacin relative 
to the total quinolone antibacterial cost, 
despite its higher prescribing rate, is an 
indication that other quinolones should be 
restricted to situations in which ciprofloxacin 
is not indicated. Combination of ciprofloxacin, 
doxycycline and metronidazole, which was 
widely used in this study in syndromic 
management of STIs, have previously been 
evaluated [16].  Low rate of MCS tests, poor 
follow-up, and very low test of cure in this 
study make it difficult to ascertain the actual 
degree of cure achieved. Moodley et al [16] 
examined the use of a syndromic algorithm in 
rural South Africa among 616 women. The 
women were treated with ciprofloxacin 500 
mg in one dose, doxycycline 200 mg daily for 
7 days, metronidazole tablet 2 g in a single 
dose, and metronidazole 2 g daily for 5 days 
for women with lower abdominal pain. The 
cure rates for chlamydia, gonorrhoea and 
trichonomas ranged from 78 to 90 %. 
However, only 52 % of women with vaginosis 
responded to therapy.     
 
In the present study, other frequently 
prescribed drugs include erythromycin and 
metronidazole and this was at a much lower 
cost to patients than the quilolones.  These 
agents are affordable to most patients but 
should be used rationally. Misuse should be 
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avoided to prevent or minimise resistance 
development, thereby reducing costs of 
antibacterial therapy. The drug distribution 
system in Nigeria needs to be improved upon 
and over the counter sales of antibacterial 
agents need to be vigorously checked. 
Regulatory institutions should be 
strengthened to achieve this in order to 
minimize bacterial resistance to these life-
saving antibacterial agents that are rapidly 
losing value. Cephalosporins, which were 
prescribed at a very low rate, constituted a 
relatively high cost of antibacterial therapy.  
This implies their usage has to be closely 
monitored from an economic perspective to 
minimize the huge burden of total 
antibacterial cost to the health care system.    
 
The national cost implication of antibacterial 
agents for the reported STIs prevalence of 
3.7 million in Nigeria [4] is about NGN3.85 
billion (US$29.63 million) or more. Part of this 
huge sum could be channeled to other areas 
or diseases if incidence of STIs is reduced 




Antibacterial cost to patients and the nation at 
large is enormous and this calls for prudent 
use of these agents. In addition, a greater 
proportion of the antibacterial cost is 
accounted for by few high-cost agents, the 
use of which should be evidence-based and 




The cooperation of the hospital management, 
physicians, pharmacists, medical record 
officers, nurses of Lagos University Teaching 
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